4-[8-{(E)-2-[4-(4-Phenylbutoxy)phenyl]vinyl}-2-(1H-tetraazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid

ID: ALA3403186

Chembl Id: CHEMBL3403186

PubChem CID: 11261220

Max Phase: Preclinical

Molecular Formula: C31H33N5O4

Molecular Weight: 539.64

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)CCCN1CC(c2nnn[nH]2)Oc2c(/C=C/c3ccc(OCCCCc4ccccc4)cc3)cccc21

Standard InChI:  InChI=1S/C31H33N5O4/c37-29(38)13-7-20-36-22-28(31-32-34-35-33-31)40-30-25(11-6-12-27(30)36)17-14-24-15-18-26(19-16-24)39-21-5-4-10-23-8-2-1-3-9-23/h1-3,6,8-9,11-12,14-19,28H,4-5,7,10,13,20-22H2,(H,37,38)(H,32,33,34,35)/b17-14+

Standard InChI Key:  ULSLRSDZZLBPFE-SAPNQHFASA-N

Associated Targets(Human)

CYSLTR1 Tclin Cysteinyl leukotriene receptor 1 (2118 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYSLTR2 Tchem Cysteinyl leukotriene receptor 2 (135 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 539.64Molecular Weight (Monoisotopic): 539.2533AlogP: 5.58#Rotatable Bonds: 13
Polar Surface Area: 113.46Molecular Species: ACIDHBA: 7HBD: 2
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.49CX Basic pKa: 1.46CX LogP: 6.11CX LogD: 1.26
Aromatic Rings: 4Heavy Atoms: 40QED Weighted: 0.17Np Likeness Score: -0.43

References

1. Itadani S, Takahashi S, Ima M, Sekiguchi T, Aratani Y, Egashira H, Matsumura N, Inoue A, Yonetomi Y, Fujita M, Nakayama Y, Takeuchi J..  (2015)  Discovery of a potent, orally available dual CysLT₁ and CysLT₂ antagonist with dicarboxylic acid.,  23  (9): [PMID:25800431] [10.1016/j.bmc.2015.03.011]

Source